Latest News

Catch up on any of the neurology news headlines you may have missed in September 2025, compiled into 1 place by the NeurologyLive® team.

A recent study reveals the significant economic burden of Angelman syndrome, highlighting rising healthcare costs and ongoing therapeutic developments.

A post hoc analysis of the phase 3 EPIDYS trial presented at CNS 2025 revealed that givinostat delayed disease progression in 2 distinct age groups of patients with Duchenne muscular dystrophy.

A recent analysis highlights the link between vastus lateralis fat fraction and treatment outcomes in Duchenne muscular dystrophy patients using givinostat.

Neflamapimod treatment led to slowing of clinical worsening, as assessed by Clinical Dementia Rating-Sum of Boxes, when drug concentrations were achieved.

The BeeLine trial is a placebo-controlled study designed to evaluate radiprodil’s impact on both seizure frequency and non-seizure symptoms associated with GRIN-NDD.

New data reveals bemdaneprocel, an innovative cell therapy for Parkinson disease, shows promising safety and efficacy over 36 months, paving the way for future trials.

Yuichi Iwaki, MD, PhD, chief executive officer at MediciNova, spoke on ibudilast’s mechanism of action, its role in the COMBAT-ALS trial, and its potential impact across neurodegenerative disease care.

A new phase 2 trial explores probiotics' potential to alleviate depression and mood disorders in patients with Parkinson disease, linking gut health to mental well-being.

Results from the extension phase of the IB1001-203 study, presented as a late-breaker at MDS 2025, suggest N-acetyl-L-leucine prevented worsening of disease progression in patients with ataxia-telangiectasia.

New heatmap analysis reveals continuous apomorphine infusion significantly improves ON time and reduces OFF episodes in patients with Parkinson disease.

In the MOXIe open-label extension study presented at MDS 2025, omaveloxolone treatment was associated with no significant disease progression in bulbar function or upper limb coordination.

Valbenazine shows significant improvements in physical, social, and emotional outcomes for tardive dyskinesia patients, as revealed in a recent study.